UrologyNews.net

Urology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Neurobase.it

Search results for "Androgen deprivation therapy"

Androgen deprivation therapy, which blocks steroid hormones called androgens, is used in around 50% of prostate cancer patients. It is recommended for locally advanced and metastatic prostate cancer. ...


In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy ( ADT ) was associated with a significantly increased risk of acute kidney injury, ...


In a phase III clinical trial, the hormone therapy Enzalutamide ( Xtandi ) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation thera ...


A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy ( ADT ), a testosterone-lowering therapy and a common treatment for ...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with androgen deprivation therapy ( ADT ), demonstrated a significant improv ...


New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San Francisco, and were simultaneously published in The New England Journal of M ...


Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic castration refractory prostate cancer ( mCRPC ). Per SW ...